Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD
Key facts
- Who runs it
- Northwestern University
- Where
- Bethesda, Chicago, and Fort Bragg, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 175 people, planned
- Started
- 2 Jul 2025
- Expected to end
- 30 Apr 2028
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Group A active comparator
- Group B active comparator
- Group C Experimental
- Group D Placebo Comparator
- Record updated
- 1 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Adults 18 years or older
- Stable doses of medications for > 2 weeks for TBI and/or PTSD
- For TBI-associated headache with or without PTSD: HIT-6 score of >/=53. For PTSD with or without TBI-associated headache: PCL-5 score >/=33 OR. For those with TBI and PTSD, and a HIT-6 score < 53 and PCL-5 score of <33, individuals with a HIT-6 score of 50-52 and a PCL-5 score of 31 or 32 will be included
- Duration of chronic TBI or PTSD > 3 months
Who cannot take part
- For TBI, prior history of headache that can explain the headache intensity (i.e., headache not attributable to TBI)
- Serious medical or psychiatric conditions other than TBI or PTSD that could affect cognition (e.g., dementia, Parkinson's Disease)
- Active psychosis or poorly controlled non-injury or PTSD-related psychiatric condition (e.g., bipolar disorder)
- Poorly controlled medical conditions that could be exacerbated by treatment (e.g., unstable angina)
- Pregnancy (women of childbearing age who can become pregnant will have to take a pregnancy test)
- Ketamine infusion or SGB within the past 6 months
- Elevated intracranial pressure
- Non-fluency in English (poor generalizability to military and veteran populations, instruments not validated for use or translated in many languages)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Posttraumatic headache or posttraumatic stress disorder
This trial is currently available in United States.
- Walter Reed National Military Medical CenterBethesda, United StatesContact: Elsa Ermer, PhDTaking people
- Anesthesiology Pain Medicine CenterChicago, United StatesContact: Jordan WoodTaking people
- Womack Army Medical CenterFort Bragg, United StatesContact: Min H Chang, MDNot yet recruiting
About the trial
What the trial wants to find out
Post-Traumatic Stress Disorder (PTSD) and traumatic brain injury (TBI) with associated headache are amongst the most common injuries sustained by our deployed forces in Iraq and Afghanistan, as well as in more recent conflicts in Eastern Europe and the Middle East. This study aims to determine whether a procedural intervention (stellate ganglion block (SGB)) or medication (ketamine), alone or in combination, can alleviate PTSD and TBI-associated headache. Determining efficacious treatments in a randomized, double-blind, placebo-controlled, multicenter study trial may improve quality of life in those with TBI and PTSD, and identifying factors associated with treatment outcome (personalized medicine) may enhance selection, thereby improving the risk: benefit and cost-effectiveness ratios.
Read full original descriptionShow less
Primary Objectives:
1. To determine the efficacy of SGB and ketamine infusion as stand-alone treatments for TBI-related headache; 2. To determine the efficacy of SGB and ketamine infusion as stand-alone treatments for PTSD; 3. To determine the comparative effectiveness of SGB and ketamine infusion, and the effect of combination treatment on TBI-related headache and PTSD; 4. Exploratory Aim 1: To determine the effects of SGB, ketamine infusion, and the combination on structural and functional MRI, biomarker levels and pain thresholds and tolerance; 5. Exploratory Aim 2: To identify factors associated with treatment responders overall and for individual treatment groups.
Secondary Objectives:
1. Exploratory Aim 1: To determine the effects of SGB, ketamine infusion, and the combination on structural and functional MRI, biomarker levels and pain thresholds and tolerance (Biomedical levels and MRI not included at Northwestern University Site). 2. Exploratory Aim 2: To identify factors associated with treatment responders overall and for individual treatment groups.
The 4 groups in the trial
- Group A =Stellate ganglion block (SGB) with bupivacaine (LA) plus placebo ketamine (midazolam)Existing treatment, for comparison
Stellate ganglion block with the local anesthetic (LA) bupivacaine and placebo (1-7 mg midazolam + normal saline) ketamine. The stellate ganglion block will be performed with approximately 8 mL bupivacaine using ultrasound or fluoroscopic guidance. The placebo ketamine will consist of an initial 1-4 mg bolus of midazolam followed by boluses or an infusion (in normal saline) of midazolam up to 7 mg, over 30-60 minutes.
Treatment: Group A active comparator
- Group B = Sham SGB plus ketamine infusionExisting treatment, for comparison
Sham SGB will be 1-2 mL of saline given subcutaneously using ultrasound or fluoroscopic guidance. The ketamine will consist of Prior to the sham Stellate Ganglion Block procedure, the study drug ketamine or normal saline will be administered by one of the study team physicians. 100 ml bag will be administered by bolus/infusion or intermittent boluses up to 0.3 mg/kg). The ketamine infusion will start before the sham block where patients will be given 1-4 mg of midazolam + up to 0.3 mg/kg of ketamine, as bolus doses. Over the next 30-60 minutes patients will receive between 0.5-1 mg/kg total dose of ketamine, + additional midazolam as needed.
Treatment: Group B active comparator
- Group C = Stellate ganglion block (SGB) with bupivacaine LA plus ketamine infusionTreatment being tested
These patients will receive both SGB with bupivacaine + ketamine as described above.
Treatment: Group C Experimental
- Group D = Sham SGB plus placebo ketamine (midazolam)Placebo, for comparison
These patients will receive the sham SGB + placebo ketamine as described above.
Treatment: Group D Placebo Comparator
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Comparing Ketamine, Stellate Ganglion Blocks and Combination Treatment to Sham Therapies for Traumatic Brain Injury-Associated Headaches and Post-Traumatic Stress Disorder
- Criteria questions
- Built from NCT06608277, who can take part
- Publications
- Record updated
- 1 May 2026